Phosphodiesterase Type 5 Inhibitors for High-Altitude Pulmonary Hypertension: A Meta-Analysis

Author： Jin Bo   Luo Xin-Ping   Ni Huan-Chun   Shi Hai-Ming  

Publisher： Adis International

ISSN： 1173-2563

Source： Clinical Drug Investigation, Vol.30, Iss.4, 2010-04, pp. : 259-265

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Update on Drug Interactions With Phosphodiesterase-5 Inhibitors Prescribed as First-Line Therapy for Patients with Erectile Dysfunction or Pulmonary Hypertension

By  

Current Drug Metabolism, Vol. 14, Iss. 2, 2013-02 ,pp. : 265-269

Bentham Science Publishers

Access to resources Recommend Favorite

Phosphodiesterase Type 5 Inhibitors: Unmet Needs

By  

Current Pharmaceutical Design, Vol. 15, Iss. 30, 2009-10 ,pp. : 3476-3485

Bentham Science Publishers

Access to resources Recommend Favorite

The genetic basis of high-altitude pulmonary oedema

By Mortimer H.   Patel S.   Peacock A.J.  

Pharmacology and Therapeutics, Vol. 101, Iss. 2, 2004-02 ,pp. : 183-192

Elsevier

Access to resources Recommend Favorite

Salmeterol reduces risk of high-altitude pulmonary oedema

By  

Inpharma, Vol. 1, Iss. 1340, 2002-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction

By Dorsey Philip   Keel Christopher   Klavens Meghan   Hellstrom Wayne JG  

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 7, 2010-05 ,pp. : 1109-1122

Informa Healthcare

Access to resources Recommend Favorite